Technetium-99m based small molecule radiopharmaceuticals and radiotracers targeting inflammation and infection.
Sign Up to like & getrecommendations! Published in 2017 at "Dalton transactions"
DOI: 10.1039/c7dt01735a
Abstract: In nuclear medicine, the detection of inflamed and infected lesions is of growing interest. Extensive efforts have been made to develop radiopharmaceuticals specific for inflammation or for discriminating sterile inflammation from infection. 99mTc is the… read more here.
Keywords: small molecule; inflammation; inflammation infection; 99mtc labelled ... See more keywords
The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist
Sign Up to like & getrecommendations! Published in 2018 at "EJNMMI Research"
DOI: 10.1186/s13550-018-0428-y
Abstract: BackgroundSomatostatin receptor targeting radiopeptides are successfully being used to image, stage, and monitor patients with neuroendocrine tumours. They are exclusively agonists that internalise upon binding to the relevant receptor. According to recent reports, antagonists may… read more here.
Keywords: labelled somatostatin; chelator; somatostatin receptor; 99mtc labelled ... See more keywords
Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15030885
Abstract: Broad availability and cost-effectiveness of 99Mo/99mTc generators worldwide support the use, and thus the development, of novel 99mTc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms patient management focused on somatostatin receptor… read more here.
Keywords: development; labelled sst2; sst2 antagonist; 99mtc labelled ... See more keywords